Clinical trials: Genital Neoplasms, Male
Prostate Cancer
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer
The primary objective of the trial is to assess if GnRH antagonists in combination with external beam radiation therapy improve progression free survival (progression that can be biological, clinical, or death) compared to GnRH…
- Trial name
- PEGASUS (NCT02799706)
- Testing
- Degarelix, approved GnRH agonist, Radiotherapy
- Where
- 39 sites in Belgium, Denmark and 6 more
- Volunteers
- 885 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Low Dose Supplemental External Radiation With Pd-103 Versus Pd-103 Alone for Prostate Cancer
The primary purpose of this study is to evaluate two treatment regimens for prostate cancer, prostate implant with 20 Gy of external beam radiation therapy versus prostate implant with 0 Gy of external beam radiation therapy.
- Trial name
- NCT00241384
- Testing
- External beam radiation, Pd-103
- Where
- 2 sites in United States
- Volunteers
- 396 people
- Sponsor
- Schiffler Cancer Center
Prostate Cancer, Prostate Adenocarcinoma
A Study of Lower Dose Radiation Therapy for People With Prostate Cancer
The purpose of this study is to see whether giving a lower (de-escalated) dose of radiation therapy to some parts of the prostate can reduce side effects compared to giving the same (uniform) dose of radiation therapy to the…
- Trial name
- NCT07635238
- Testing
- MR-guided Stereotactic Body Radiation Therapy
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stage I Prostate Cancer AJCC v7, Stage II Prostate Cancer AJCC v7
Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer
This study collects urine and stool samples to determine the ability to identify changes in the microbiome (bacteria, fungi, and viruses that live in the gut and urine) of patients with prostate cancer during androgen deprivation…
- Conditions
- Stage I Prostate Cancer AJCC v7, Stage II Prostate Cancer AJCC v7, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7
- Trial name
- NCT04775355
- Testing
- Biospecimen Collection, Electronic Health Record Review, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer
Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer
In this study, the investigators intend to validate 18F-DCFPyL test-retest reproducibility in metastatic lesions, in order to investigate whether it serves as a reliable response assessment tool, both to interpret existing…
- Trial name
- NCT03793543
- Testing
- 18F-DCFPyL Injection
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Papillomavirus Infections
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
The purpose of this study is to evaluate the efficacy, immunogenicity and safety of the 9vHPV vaccine in men 20 to 45 years of age.
- Trial name
- NCT04199689
- Testing
- 9vHPV Vaccine
- Where
- 103 sites in United States, Belgium and 14 more
- Volunteers
- 6,033 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
MR-guided Focused Ultrasound Treatment of Prostate Cancer: Focal Therapy for Locally Non-Advanced Disease
Since prostate specific antigen (PSA) was introduced as a clinical screening tool for prostate cancer, more men are diagnosed with small foci of cancers instead of the advanced disease.
- Trial name
- NCT01522118
- Testing
- ExAblate 2100; InSightec
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- University of Roma La Sapienza
Prostate Cancer, Bladder Cancer
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
To evaluate the safety of NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine given by particle-mediated epidermal delivery (PMED) in patients with tumor types known to express NY-ESO-1 or LAGE-1.
- Conditions
- Prostate Cancer, Bladder Cancer, Non-small Cell Lung Cancer, Esophageal Cancer
- Trial name
- NCT00199849
- Testing
- NY-ESO-1 Plasmid DNA Cancer Vaccine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ludwig Institute for Cancer Research
Prostate Cancer
Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer
The goal of this clinical trial is to evaluate the outcomes of a shorter treatment duration (12 months) with an androgen receptor pathway inhibitor (ARPI), in this study Apalutamide or Enzalutamide, in patients with low-volume…
- Trial name
- Apa/Enza-short (NCT07260435)
- Testing
- ADT plus only 12 months of ARPI, ADT plus continued ARPI
- Where
- 26 sites in Netherlands
- Volunteers
- 400 people
- Sponsor
- Nick Beije
Prostate Cancer
Early DVC Ligation and Urinary Continence Recovery After RARP
The aim of the study is to evaluate the impact of early deep venous complex ligation (eDVCL) in patients affected by clinically localized prostate cancer (PCa) undergoing robot-assisted radical prostatectomy with or without…
- Trial name
- NCT03368378
- Testing
- Early DVC ligation
- Where
- Italy
- Volunteers
- 312 people
- Sponsor
- IRCCS San Raffaele
Prostate Cancer
A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.
- Trial name
- NCT00036543
- Testing
- Atrasentan
- Where
- 232 sites in United States, Australia and 16 more
- Volunteers
- 1,000 people
- Sponsor
- Abbott
Penile Carcinoma
Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer
This is a phase II clinical trial evaluating activity, safety and patients reported outcomes of first-line pembrolizumab plus cisplatin (or carboplatin) plus 5-FU for patients with advanced penile squamous cell carcinoma.
- Trial name
- HERCULES (NCT04224740)
- Testing
- Pembrolizumab, Standard of care therapy
- Where
- 11 sites in Brazil
- Volunteers
- 37 people
- Sponsor
- Latin American Cooperative Oncology Group
Prostate Cancer
Tranexamic Acid's Effects in Patients Undergoing Laparoscopic Radical Prostatectomy
The study is randomized, placebo-controlled, double-blind clinical trial that aims to check whether tranexamic acid's use in videolaparoscopic radical prostatectomy intraoperative is effective in decrease serum hemoglobin drop…
- Trial name
- Transamin (NCT05816668)
- Testing
- Tranexamic acid
- Volunteers
- 122 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Prostate Cancer
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body…
- Trial name
- ASCENDE-SBRT (NCT06235697)
- Testing
- Radiation, Radiation SBRT only, ADT
- Where
- 57 sites in United States, Canada
- Volunteers
- 710 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Adenocarcinoma, Stage I Prostate Cancer
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
This trial studies the side effects and how well high-dose brachytherapy works in treating patients with prostate cancer that has not spread to other parts of the body.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT02346253
- Testing
- Internal Radiation Therapy, Bicalutamide, Leuprolide Acetate
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Stanford University
Prostate Cancer
Biological Therapy in Treating Patients With Prostate Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells including natural killer cells to kill prostate cancer cells. Interferon gamma may interfere with the growth of the cancer cells.
- Trial name
- NCT00002637
- Testing
- aldesleukin, gene-modified tumor cell vaccine therapy, recombinant interferon gamma
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Study In Urology Practices Looking At Impact Of OncotypeDX GPS Test On Men Choosing And Remaining On Active Surveillance
Genomic Health's OncotypeDX® Prostate Cancer Assay is a commercially available laboratory test that measures the activity of certain genes in prostate cancer.
- Trial name
- NCT03502213
- Volunteers
- 489 people
- Sponsor
- Genomic Health®, Inc.
Metastatic Prostate Cancer
Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients
The purpose of this study is to assess the impact of the addition of metformin to abiraterone on survival in patients with metastatic prostate cancer
- Trial name
- MetAb-Pro (NCT01677897)
- Testing
- Metformin
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- Kantonsspital Graubünden
Prostate Cancer
Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer
This is a study for men who have locally-advanced prostate cancer and are eligible to undergo prostatectomy. Standard treatment is prostatectomy alone, but there is a chance that cancer may spread to other organs in the future…
- Trial name
- NCT02494713
- Testing
- Degarelix, Doxorubicin, Ketoconazole
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- The University of Texas Health Science Center, Houston
Prostate Cancer
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
This clinical trial will determine whether the addition of radiotherapy to standard of care systemic therapy improves objective progression-free survival compared to systemic therapy alone in patients with oligometastatic…
- Trial name
- NCT03556904
- Testing
- Ablative Radiation Therapy, Hormone therapy or chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Michigan Rogel Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.